Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma
Authors:
- 1 November 2022
- journal article
- research article
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (5) , 1842-1852
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Cancer Prevention and Research Institute of Texas (RP180672)
- Cancer Prevention and Research Institute of Texas (RR024574)
- Cancer Prevention and Research Institute of Texas (CPRIT RP200443)
- National Institutes of Health (CA125123)
- National Cancer Institute (R37CA248478)
This publication has 39 references indexed in Scilit:
- Robust enumeration of cell subsets from tissue expression profilesNature Methods, 2015
- Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural MesotheliomaCancer Research, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic ContinuumScience, 2011
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failureOncogene, 2010
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomasVirchows Archiv, 2008
- The Regulation of INK4/ARF in Cancer and AgingCell, 2006
- Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic PredictionCancer Research, 2006
- Role of the INK4a Locus in Tumor Suppression and Cell MortalityCell, 1996